Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7528890 | 0.88 | CYP1A2 (0.53) | CYP1A2CYP2C19CYP2D6SIGMAR1CTNNB1 | |
| SCHEMBL8686986 | 0.86 | CYP1A2 (0.44) | CYP1A2CYP2C19CYP2D6SIGMAR1CTNNB1 | |
| SCHEMBL8877478 | 0.83 | CYP1A2 (0.48) | CYP1A2CYP2C19CYP2D6SIGMAR1CTNNB1 | |
| SCHEMBL5830799 | 0.83 | SIGMAR1 (0.46) | CYP1A2CYP2C19CYP2D6SIGMAR1CTNNB1 | |
| SCHEMBL9395129 | 0.81 | CTNNB1 (0.54) | CYP1A2CYP2C19CYP2D6SIGMAR1CTNNB1 | |
| SCHEMBL4817621 | 0.81 | CYP1A2 (0.50) | CYP1A2CYP2C19CYP2D6SIGMAR1CTNNB1 | |
| SCHEMBL331127 | 0.80 | GABRA1 (0.54) | CYP1A2CYP2C19CYP2D6SIGMAR1CTNNB1 | |
| SCHEMBL8325161 | 0.80 | SIGMAR1 (0.56) | CYP1A2CYP2C19CYP2D6SIGMAR1CTNNB1 | |
| SCHEMBL27318580 | 0.80 | CYP1A2 (0.46) | CYP1A2CYP2C19CYP2D6SIGMAR1CTNNB1 | |
| SCHEMBL10456008 | 0.79 | GABRA1 (0.52) | CYP1A2CYP2C19CYP2D6SIGMAR1CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358396-B2 | Preparation of optically active amines | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-15 | — | — | US | disclosed |
| US-20070155971-A1 | Chiral diphosphorus compounds and their transition metal complexes | Source Global, PBC | 2007-07-05 | — | — | US | disclosed |
| US-7193092-B2 | Chiral diphosphorus compounds and their transition metal complexes | LANXESS DEUTSCHLAND GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| US-7078226-B1 | Method for producing optically active amines | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20060122429-A1 | Preparation of optically active amines | DITRICH KLAUS | 2006-06-08 | — | — | US | disclosed |
| EP-1400527-B1 | Chiral diphosphorus compounds and transition metal complexes thereof | LANXESS DEUTSCHLAND GMBH (DE) | 2006-03-22 | — | — | EP | disclosed |
| EP-1398319-B1 | Chiral monophosphorus compounds and transition metal complexes thereof | LANXESS DEUTSCHLAND GMBH (DE) | 2005-11-09 | — | — | EP | disclosed |
| CN-1204262-C | Method for producing optically active amines | BASF AG (DE) | 2005-06-01 | — | — | CN | disclosed |
| US-20050080047-A1 | Chiral diphosphorus compounds and their transition metal complexes | LANXESS DEUTSCHLAND GMBH (DE) | 2005-04-14 | — | — | US | disclosed |
| CN-1195764-C | Transition metal complex, preparation method and use thereof | BASF AG (DE) | 2005-04-06 | — | — | CN | disclosed |
| CN-1147248-A | N- (3-pyrrolidinyl) benzamide derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1997-04-09 | — | — | CN | disclosed |
| CN-1143364-A | 5-HT3 receptor agonist, novel thiazole derivative, and intermediate thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1997-02-19 | — | — | CN | disclosed |
| EP-0757985-A1 | N-(3-PYRROLIDINYL)BENZAMIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0749966-A1 | 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| CN-1105354-A | Novel alkamine derivative and slat of same | YAMANOUCHI PHARMA CO LTD (JP) | 1995-07-19 | — | — | CN | disclosed |
| CN-1051178-A | New heterogeneous ring compound and preparation method thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1991-05-08 | — | — | CN | disclosed |
| EP-0425134-A1 | Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122429-A1 | Preparation of optically active amines | MAOA, MAOB, NAAA | CYP1A2 165/4885CYP2C19 269/4885CYP2D6 616/4885 |
| US-20070155971-A1 | Chiral diphosphorus compounds and their transition metal complexes | CDIPT, DCPS, PIN1 | CYP1A2 1320/4885CYP2C19 1457/4885CYP2D6 201/4885 |
| US-20050080047-A1 | Chiral diphosphorus compounds and their transition metal complexes | CDIPT, DCPS, PIN1 | CYP1A2 1320/4885CYP2C19 1457/4885CYP2D6 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.